Tag: B7-H3
SOT106: An LRRC15-Directed ADC Moves Toward the Clinic in Sarcoma
SOT106, an investigational antibody-drug conjugate directed against leucine-rich repeat-containing 15 (LRRC15), is moving toward first-in-human testing after receiving four U.S. Food and Drug Administration...
Risvutatug Rezetecan Demonstrates Overall Survival Benefit Over Topotecan in Relapsed Small...
Interim results from the pivotal Phase 3 ARTEMIS-008 trial (NCT06498479) show that risvutatug rezetecan, a B7-H3-directed antibody-drug conjugate, significantly reduced the risk of death...
B7-H3 Antibody-Drug Conjugates Gain Momentum as Frontline Standards Shift Across Solid...
B7-H3 Antibody-Drug Conjugates Gain Momentum as Frontline Standards Shift Across Solid Tumors
Ifinatamab Deruxtecan Receives FDA Priority Review for Previously Treated Extensive-Stage Small...
Ifinatamab Deruxtecan (previously known as DS-7300a), a B7-H3-directed antibody-drug conjugate being developed by Daiichi Sankyo and Merck & Co. (known as MSD outside of the United States and Canada), could offer a First-in-Class option for patients diagnosed with extensive-stage small cell lung cancer (ES-SCLC) following platinum-based chemotherapy.
GSK and Duality Biologics Sign Option Agreement for DB-1324
GSK and Duality Biologics have entered into an exclusive option agreement for developing and commercializing DB-1324, a potentially best-in-class antibody-drug conjugate (ADC) candidate.
Rapid Advances in the Development of Novel ADCs Targeting B7-H3 and...
With five antibody-drug conjugates (ADC) having received approval from the United States Food and Drug Administration (FDA) and other regulators around the world and...
MacroGenics and Synthon Biopharmaceuticals Sign Agreement
MacroGenics and Synthon Biopharmaceuticals have signed an agreement to license and collaborate in he development of MGC018, an antibody-drug conjugate or ADC directed against...
